[go: up one dir, main page]

DK1408976T5 - Behandling af ADHD (Attention deficit hyperactivity disorder) - Google Patents

Behandling af ADHD (Attention deficit hyperactivity disorder)

Info

Publication number
DK1408976T5
DK1408976T5 DK02756536.5T DK02756536T DK1408976T5 DK 1408976 T5 DK1408976 T5 DK 1408976T5 DK 02756536 T DK02756536 T DK 02756536T DK 1408976 T5 DK1408976 T5 DK 1408976T5
Authority
DK
Denmark
Prior art keywords
adhd
attention deficit
hyperactivity disorder
treatment
deficit hyperactivity
Prior art date
Application number
DK02756536.5T
Other languages
English (en)
Other versions
DK1408976T3 (da
Inventor
Daniela Brunner
Daniel W Goodman
Original Assignee
Psychogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psychogenics Inc filed Critical Psychogenics Inc
Publication of DK1408976T3 publication Critical patent/DK1408976T3/da
Application granted granted Critical
Publication of DK1408976T5 publication Critical patent/DK1408976T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK02756536.5T 2001-07-20 2002-07-19 Behandling af ADHD (Attention deficit hyperactivity disorder) DK1408976T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30682501P 2001-07-20 2001-07-20
US38293102P 2002-05-23 2002-05-23
PCT/US2002/023081 WO2003007956A1 (en) 2001-07-20 2002-07-19 Treatment for attention-deficit hyperactivity disorder

Publications (2)

Publication Number Publication Date
DK1408976T3 DK1408976T3 (da) 2009-06-29
DK1408976T5 true DK1408976T5 (da) 2011-01-10

Family

ID=26975388

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02756536.5T DK1408976T5 (da) 2001-07-20 2002-07-19 Behandling af ADHD (Attention deficit hyperactivity disorder)

Country Status (10)

Country Link
US (5) US7504395B2 (da)
EP (2) EP1408976B3 (da)
JP (1) JP5080716B2 (da)
AT (1) ATE424825T1 (da)
AU (2) AU2002322539B2 (da)
CA (1) CA2453837C (da)
DE (1) DE60231507D1 (da)
DK (1) DK1408976T5 (da)
ES (1) ES2323451T7 (da)
WO (1) WO2003007956A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
EP1408976B3 (en) * 2001-07-20 2010-08-25 Psychogenics Inc. Treatment for attention-deficit hyperactivity disorder
US8134029B2 (en) 2002-09-16 2012-03-13 Sunovion Pharmaceuticals Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
US8751031B2 (en) * 2004-02-06 2014-06-10 Zircore, Llc System and method for mass custom manufacturing of dental crowns and crown components
WO2007006003A2 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
US9066903B2 (en) 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
AU2009255333B2 (en) * 2008-05-30 2015-07-09 Psychogenics, Inc. Treatment for neurological and mental disorders
CA2759180A1 (en) * 2009-05-13 2010-11-18 Sunovion Pharmaceuticals Inc. Compositions comprising transnorsertraline and serotonin receptor 1a agonists/antagonists and uses thereof
NZ597319A (en) * 2009-06-25 2014-06-27 Alcobra Ltd A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition
EP2448580A1 (en) 2009-06-30 2012-05-09 Merz Pharma GmbH & Co. KGaA Eltoprazine for the treatment of anxiety
WO2011000563A1 (en) 2009-06-30 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Eltoprazine for the treatment of weight disorders
WO2011000562A1 (en) 2009-06-30 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Eltoprazine for the treatment of certain movement disorders
WO2011000564A1 (en) 2009-06-30 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Eltoprazine for the treatment of drug addiction
US8469711B2 (en) * 2009-09-29 2013-06-25 Advanced Training System Llc System, method and apparatus for driver training of shifting
WO2014180556A1 (en) * 2013-05-06 2014-11-13 Merz Pharma Gmbh & Co. Kgaa Arylpiperazines
JP7406285B1 (ja) 2023-03-09 2023-12-27 国立大学法人島根大学 ビリルビン誘発性神経機能障害、黄疸を伴う精神疾患、又はビリルビンｕｄｐ－グルクロン酸転移酵素遺伝子変異に起因する精神疾患を治療、予防又は管理するための医薬組成物

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039653A (en) * 1974-01-23 1977-08-02 Defoney, Brenman, Mayes & Baron Long-acting articles for oral delivery and process
CH653021A5 (fr) 1981-04-24 1985-12-13 Delalande Sa Derives piperidino, piperazino et homopiperazino, n-substitues par un groupe heterocyclique aromatique, leur procede de preparation et composition therapeutique les contenant.
FR2524312B1 (fr) * 1982-04-01 1985-10-04 Tech Cuir Centre Nouvelles formes de micro-encapsulation de substances medicamenteuses par des couches homogenes de collagene natif
AU577802B2 (en) 1983-10-17 1988-10-06 Duphar International Research B.V. Blood-pressure lowering piperazine derivatives
DE3571436D1 (en) 1984-12-21 1989-08-17 Duphar Int Res New pharmaceutical compositions having anti-psychotic properties
EP0189612B1 (en) 1984-12-21 1992-11-04 Duphar International Research B.V New pharmaceutical compositions having a psychotropic activity
GB8521494D0 (en) * 1985-08-29 1985-10-02 Zyma Sa Controlled release tablet
US4797286A (en) * 1985-11-12 1989-01-10 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
NZ219380A (en) 1986-02-27 1990-06-26 Duphar Int Res (n-piperidinyl)- and (n-piperazinyl)-methylazole derivatives and pharmaceutical compositions
GB8613689D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
IE74200B1 (en) 1987-09-11 1997-07-16 Duphar Int Res Anxiolytically active piperazine derivatives
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
CA2004670A1 (en) 1988-12-08 1990-06-08 Jan Hartog Anxiolytically active piperazine derivatives
GB8830312D0 (en) 1988-12-28 1989-02-22 Lundbeck & Co As H Heterocyclic compounds
SE8904361D0 (sv) 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
FR2670491B1 (fr) 1990-12-14 1993-02-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les renfermant.
AU645681B2 (en) 1991-05-02 1994-01-20 John Wyeth & Brother Limited Piperazine derivatives
IT1251144B (it) 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
GB9125900D0 (en) 1991-12-05 1992-02-05 Wyeth John & Brother Ltd Piperazine derivatives
EP0556889A1 (en) 1992-02-18 1993-08-25 Duphar International Research B.V Method of preparing aryl(homo)piperazines
FR2692264B1 (fr) 1992-06-12 1994-08-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
DK148392D0 (da) 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
EP0605033B1 (en) 1992-12-21 1999-07-21 Duphar International Research B.V Enzymatic process for the stereoselective preparation of a hetero-bicyclic alcohol enantiomer
RU2118322C1 (ru) 1993-07-05 1998-08-27 Дюфар Интернэшнл Рисерч Б.В. 2,3-дигидро-1,4-бензодиокси-5-ил-пиперазиновые производные или их соли
EP0711554A4 (en) * 1993-07-28 1997-07-23 Nippon Shinyaku Co Ltd ANTIDEPRESSANT
JPH09503773A (ja) 1993-10-19 1997-04-15 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ−１ｄレセプター拮抗剤用のベンズアニリド誘導体
EP0650964A1 (en) 1993-11-02 1995-05-03 Duphar International Research B.V 1 2H-1-benzopyran-2-one-8-yl -piperazine derivatives
IL112764A0 (en) 1994-03-18 1995-05-26 Ferrer Int New chromene derivatives
NZ284853A (en) 1994-06-29 1998-12-23 Pfizer 1-(azacycloalkyl)-7-(arylalkoxy)naphthalene derivatives; medicaments
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
EP0710481A1 (en) 1994-11-02 1996-05-08 Duphar International Research B.V Use of flesinoxan for cognition enhancement
WO1996017831A1 (de) 1994-12-07 1996-06-13 Byk Gulden Lomberg Chemische Fabrik Gmbh Uracilderivate
US5741789A (en) 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
WO1997003067A1 (en) 1995-07-13 1997-01-30 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
GB9514901D0 (en) 1995-07-20 1995-09-20 American Home Prod Piperazine derivatives
JPH11511156A (ja) 1995-08-11 1999-09-28 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ビフェニル（チオ）アミドおよびビフェニルエタン（チオ）オン誘導体、その製造方法ならびに５−ｈｔ▲下１ｄ▼ 受容体拮抗薬としてのその使用
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
BRPI9708389B8 (pt) 1996-03-29 2015-12-08 Duphar Int Res compostos de piperazina e piperidina, composições farmacêuticas.
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
EP0932609B1 (en) 1996-10-15 2003-05-14 Wyeth AZAHETEROCYCLYMETHYL DERIVATIVES OF 2,3,8,9-TETRAHYDRO-7H-1,4-DIOXINO 2,3-e]INDOL-8-ONE
JPH10269708A (ja) 1997-03-25 1998-10-09 Hiroshi Fukuda 多信号用メモリーシステム
FR2760014B1 (fr) 1997-02-27 1999-04-09 Adir Nouveaux composes de 2-amino indane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
DE19730989A1 (de) * 1997-07-18 1999-01-21 Merck Patent Gmbh Piperazin-Derivate
ATE252575T1 (de) 1997-07-25 2003-11-15 Lundbeck & Co As H Indole und 2,3-dihydroindolderivate, ihre herstellung und verwendung
US5942244A (en) * 1997-07-31 1999-08-24 Farmo-Nat Ltd. Local oral herbal slow release tablets
ATE253058T1 (de) 1997-09-02 2003-11-15 Duphar Int Res Piperidin- und piperazin derivate als 5-ht1- rezeptor-agonisten
SE9703375D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
SE9703374D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
SE9703376D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
SE9703378D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
TW530054B (en) 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
FR2769312B1 (fr) 1997-10-03 1999-12-03 Adir Nouveaux composes de l'indanol, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IL127497A (en) 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6310066B1 (en) 1998-04-29 2001-10-30 American Home Products Corp. Antipsychotic indolyl derivatives
US6387904B2 (en) 1998-05-18 2002-05-14 Pfizer Inc Method of treating glaucoma and ischemic retinopathy
ES2204067T3 (es) 1998-05-26 2004-04-16 Pfizer Products Inc. Medicamento para el tratamiento del glaucoma y de la retinopatia isquemica.
GB9812523D0 (en) * 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6376494B1 (en) 1998-06-15 2002-04-23 American Home Products Corporation Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
CN1312802A (zh) 1998-06-15 2001-09-12 美国家用产品公司 作为5－羟色胺能药物的环烷基取代的芳基哌嗪、哌啶和四氢吡啶
UA71590C2 (en) 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives
US6242448B1 (en) 1998-12-17 2001-06-05 American Home Products Corporation Trisubstituted-oxazole derivatives as serotonin ligands
US6313126B1 (en) 1999-01-07 2001-11-06 American Home Products Corp Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
CZ20012444A3 (cs) 1999-01-07 2002-02-13 American Home Products Corporation Arylpiperazinylcyklohexylindolové deriváty pro léčbu deprese
AR022303A1 (es) 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
US6306859B1 (en) 1999-03-02 2001-10-23 American Home Products Corporation N-substituted imide derivatives with serotonergic activity
ES2162731B1 (es) 1999-06-04 2003-02-16 Faes Fabrica Espanola De Produ Nuevas arilpiperacilnilalquil-3(2h)-piridacinonas.
BR0012752A (pt) 1999-07-29 2002-04-02 Lilly Co Eli Benzofuril piperazinas e benzofuril homopiperazinas: agonistas de serotonina
DE60002583T2 (de) 1999-07-29 2004-03-25 Eli Lilly And Co., Indianapolis Benzofurylpiperazine als serotonin-agonisten
HUP0203194A3 (en) 1999-08-23 2004-01-28 Solvay Pharm Bv Phenylpiperazines, pharmaceutical compositions containing them and their use
AR027133A1 (es) 1999-12-30 2003-03-12 Lundbeck & Co As H Derivados de heteroarilo, su preparacion y uso.
CA2405971C (en) 2000-05-12 2010-03-30 Solvay Pharmaceuticals B.V. New piperazine and piperidine compounds
CA2405758A1 (en) 2000-05-12 2001-11-15 Solvay Pharmaceuticals B.V. Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders
US20020016334A1 (en) 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
DE10041574A1 (de) 2000-08-24 2002-03-07 Merck Patent Gmbh Chromenonderivate
DE10043659A1 (de) 2000-09-05 2002-03-14 Merck Patent Gmbh Arylpiperazinderivate
US7034029B2 (en) * 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
IL155443A0 (en) 2000-11-02 2003-11-23 Wyeth Corp 1- aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
US6469007B2 (en) 2000-11-28 2002-10-22 Wyeth Serotonergic agents
ES2188344B1 (es) 2000-11-29 2004-09-16 Laboratorios Vita, S.A. Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos.
AR032711A1 (es) 2001-02-21 2003-11-19 Solvay Pharm Bv Derivados de fenilpiperazina, un metodo para la preparacion de los mismos y una composicion farmaceutica que los contiene
ATE312094T1 (de) 2001-06-29 2005-12-15 Lundbeck & Co As H Neue heteroarylderivate, deren herstellung und verwendung
EP1408976B3 (en) * 2001-07-20 2010-08-25 Psychogenics Inc. Treatment for attention-deficit hyperactivity disorder
HU227237B1 (en) 2001-09-27 2010-12-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them
ITMI20012060A1 (it) 2001-10-05 2003-04-05 Recordati Chem Pharm Nuovi eterocilcli n-acilati
EP1336406A1 (en) 2002-02-14 2003-08-20 Solvay Pharmaceuticals B.V. Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity
WO2003074518A1 (en) 2002-03-06 2003-09-12 Merck Patent Gmbh Thiazole derivatives and their use d2- and 5-ht1a-receptor ligands
CN1982307A (zh) 2002-03-12 2007-06-20 惠氏公司 合成手性n－芳基哌嗪的方法
AU2003220110B2 (en) 2002-03-12 2009-04-09 Wyeth Process for making chiral 1,4-disubstituted piperazines
ES2334836T3 (es) 2002-03-12 2010-03-16 Wyeth Preparacion de 2-((2,3-dihidro-benzo(1,4)dioxin-5-il)-(2-hidroxietil)-amino)-etanol y productos intermedios correspondientes.
NZ536230A (en) 2002-05-13 2007-05-31 Hoffmann La Roche Benzoxazine derivatives as 5-hydroxytryptamine-6 (5-HT6) modulatory neurotransmitter in the brain
US20040072839A1 (en) 2002-06-14 2004-04-15 Amedeo Leonardi 1-Phenylalkylpiperazines
US20040002500A1 (en) 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
US7067518B2 (en) 2002-09-05 2006-06-27 Wyeth Pyridinyl-methyl-ethyl cyclohexanecarboxamides as serotonergic agents
US7153849B2 (en) 2002-09-12 2006-12-26 Wyeth Antidepressant arylpiperazine derivatives of hetrocycle-fused benzodioxans
WO2004041792A1 (en) 2002-11-08 2004-05-21 F. Hoffmann-La Roche Ag Substituted benzoxazinones and uses thereof
HU227592B1 (en) 2002-11-13 2011-09-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Use of substituted alkyl-piridazinone derivatives for the treatment of memory decline and learning malfunctions
US20040147581A1 (en) 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
GB0227240D0 (en) 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
DE10259244A1 (de) 2002-12-17 2004-07-01 Merck Patent Gmbh N-(Indolethyl-)cycloamin-Verbindungen
US20050004105A1 (en) 2003-01-29 2005-01-06 Emer Leahy Treatment for a attention-deficit hyperactivity disorder
ES2297386T3 (es) 2003-03-03 2008-05-01 F. Hoffmann-La Roche Ag Tetrahidroisoquinolinas 2,5-sustituidas para uso como moduladores de 5-ht6.
AU2004237961A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Treatment of bipolar disorders and associated symptoms
WO2004100955A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Anxiety treatments with ziprasidone
BRPI0410378A (pt) 2003-05-16 2006-06-13 Pfizer Prod Inc tratamento de distúrbios psicóticos e depressivos
CA2525323A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Method for enhancing cognition using ziprasidone
US20050065158A1 (en) 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
US7435738B2 (en) 2003-08-18 2008-10-14 Solvay Pharmaceuticals, Inc. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
DE602004008668T2 (de) 2003-12-09 2008-06-12 F. Hoffmann-La Roche Ag Benzoxazinderivate und deren verwendungen
MXPA06007213A (es) 2003-12-23 2006-08-18 Pfizer Prod Inc Combinacion terapeutica para la mejora de la cognicion y trastornos sicoticos.

Also Published As

Publication number Publication date
US20030050308A1 (en) 2003-03-13
US20120070494A1 (en) 2012-03-22
CA2453837C (en) 2011-10-04
EP1408976B3 (en) 2010-08-25
EP1408976A4 (en) 2007-05-16
EP1408976A1 (en) 2004-04-21
EP2036547A2 (en) 2009-03-18
US20110008425A1 (en) 2011-01-13
EP2036547A3 (en) 2009-12-23
US7504395B2 (en) 2009-03-17
JP5080716B2 (ja) 2012-11-21
US7557109B2 (en) 2009-07-07
US20060004023A1 (en) 2006-01-05
AU2007254677B2 (en) 2009-11-12
DK1408976T3 (da) 2009-06-29
JP2004538282A (ja) 2004-12-24
ES2323451T3 (es) 2009-07-16
US20090104261A1 (en) 2009-04-23
ES2323451T7 (es) 2011-08-01
HK1065478A1 (en) 2005-02-25
ATE424825T1 (de) 2009-03-15
DE60231507D1 (de) 2010-07-01
WO2003007956A1 (en) 2003-01-30
EP1408976B1 (en) 2009-03-11
AU2007254677A1 (en) 2008-01-24
AU2002322539B2 (en) 2007-09-27
CA2453837A1 (en) 2003-01-30

Similar Documents

Publication Publication Date Title
DK1408976T5 (da) Behandling af ADHD (Attention deficit hyperactivity disorder)
ATE296634T1 (de) (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen
DE60237725D1 (de) Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit
DK1503788T3 (da) Behandling af alpha-galactosidase A-deficiens
ATE542801T1 (de) Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
ATE415968T1 (de) 3,11b-cis-dihydrotetrabanezin zur behandlung von schizophrenie und anderen psychosen
CY1107911T1 (el) Διαταξη αφαιρεσεως
ATE316787T1 (de) Kombination von fenofibrat und von coenzym q10 für die behandlung der endotheliaal missfunktion
CY1109238T1 (el) Δισκιο περιεχον σετιριζινη και ψευδοεφεδρινη
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
DK1343822T3 (da) Middel til diagnosticering og behandling af CTCL
BRPI0418589A (pt) composições farmacêuticas e métodos para tratamento por insulina
DK1491212T3 (da) Middel til behandling af søvnforstyrrelser
ATE556707T1 (de) Phosphodiesesterase 4 inhibitoren zur behandlung eines kognitiven defizits
ATE400564T1 (de) Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
BR0313588A (pt) Métodos para o tratamento da demência com base em apo e genótipo
DE60335610D1 (de) Neoplasma-spezifische antikörper und deren verwendungen
DK1603584T3 (da) Aplidine til behandling af multipelt myelom
DK1530462T3 (da) 1-phenyl-2-dimethylaminomethylcyclohexanforbindelser til behandling af depressionssymtomer. smerte og inkontinens
DE50300918D1 (de) Anlage zum sterilisieren, pasteurisieren und/oder desinfizieren pump- oder rieselfaehiger medien
DE60215219D1 (de) Verwendung von darifenacin zur behandlung des harndrangs
ATE443262T1 (de) Molekulardiagnoseverfahren und behandlung von demenz mit lewy-körperchen
SE0003126D0 (sv) Method of treatment
DE60227078D1 (de) Allylmercaptocaptoprilverbindungen und deren verwendungen